This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
SS-31 improved mitochondrial respiratory capacity in TazKD mice without affecting the MLCL/CL ratio.
Why it matters
Improving mitochondrial function could lead to better treatments for Barth Syndrome, a condition with limited therapeutic options. This research highlights the potential of SS-31 as a pharmacological agent.
How the study worked
The study used TAFAZZIN knockdown mice to assess the impact of SS-31 on mitochondrial function and lipid profiles.
What this study cannot tell us
The study was conducted in mice, and results may not directly translate to humans. Further research is needed to confirm these findings in clinical settings.
Read the original research
Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
Scientific reports, 12(1), 19847
Citation
Russo, Silvia; De Rasmo, Domenico; Signorile, Anna; Corcelli, Angela; Lobasso, Simona. (2022). Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.. Scientific reports, 12(1), 19847. https://doi.org/10.1038/s41598-022-24231-4